Interview on National Public Radio with Jim Joyce, CEO of Aethlon Medical and Executive Chairman of Exosome Sciences. Its blood test appears to identify CTE – Chronic Traumatic Encephalopathy – in retired NFL players. The interview is quite informative as ...
Read More »Researchers Announce Plans for Study of Candidate Blood Test to Detect Chronic Traumatic Encephalopathy (CTE) in Former NFL Players
Results will add to Published Data Involving Candidate Biomarker to Identify & Monitor CTE Researchers with Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company, today announced plans to initiate a clinical study ...
Read More »Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
from Streetwise Reports – Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James “Jim” Joyce shares the ...
Read More »Exosomes may hold the key to diagnosing brain injuries in NFL players
from Neurology Advisor by Alicia Ciccone Researchers may have uncovered a way to detect chronic traumatic encephalopathy (CTE) in living individuals with a blood test that detects plasma exosomal tau. The preliminary results were published in the Journal of Alzheimer’s ...
Read More »Exosome Sciences To Participate In Clinical Research Study To Diagnose Chronic Traumatic Encephalopathy (CTE)
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., announced recently that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as ...
Read More »Aethlon Medical CEO Jim Joyce Discusses the Forthcoming Research Being Conducted by Aethlon’s Exosome Sciences Subsidiary
Source: Gail Dutton of The Life Sciences Report SAN FRANCISCO, CA – December 23, 2015 (Investorideas.com stocks newswire) Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD), is pioneering the potential use of an exosome-based biomarker to diagnose chronic ...
Read More »Exosome Sciences Announces Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players
SAN DIEGO, PRINCETON, N.J. and BOSTON, Sept. 26, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to ...
Read More »Expanding on Liquid Biopsies with Exosomes
A new type of liquid biopsy for solid tumors based on analyzing exosomes from the blood is being tested at Thomas Jefferson University. Thomas Jefferson University announces a partnership with Exosome Sciences Inc. to evaluate a novel liquid biopsy platform ...
Read More »Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes
Viable tumor cells actively release vesicles into the peripheral circulation and other biologic fluids, which exhibit proteins and RNAs characteristic of that cell. Researchers from Exosome Sciences, Inc demonstrated the presence of these extracellular vesicles of tumor origin within the peripheral ...
Read More »Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit
SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed ...
Read More »